Program
Ropivacaine
Also written as “TLC590”, “Ropivacaine + Clonidine + Betamethasone” and “ropivacaine”.
Its studies are mostly in Pain, Postoperative · Hernia, Inguinal · Bunion · Pain · Hallux Valgus, led by 10 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| PainReform | 40 open or running | phase 3since Nov 1, 2022 | Apr 16, 2009 | none ahead |
| Taiwan Liposome | 31 open or running | phase 3since Dec 3, 2021 | Jun 25, 2018 | none ahead |
| PHARMAFINA | 20 open or running | phase 2since Jul 31, 2025 | Jan 6, 2025 | none ahead |
| TLC Biopharmaceuticals | 22 open or running | phase 3since Oct 28, 2025 | Aug 25, 2024 | none ahead |
| AstraZeneca | 10 open or running | phase 3since Jul 28, 2006 | Jul 28, 2006 | none ahead |
| BioQ Pharma | 10 open or running | phase 3since Nov 4, 2016 | Nov 4, 2016 | none ahead |
| Cali Pharmaceuticals | 10 open or running | phase 2since Aug 14, 2021 | Aug 14, 2021 | none ahead |
| Egymedicalpedia | 10 open or running | phase 1since Sep 13, 2022 | Sep 13, 2022 | none ahead |
| Jiangsu HengRui Medicine | 11 open or running | phase 2since Sep 27, 2022 | Sep 27, 2022 | none ahead |
| Vital 5 | 10 open or running | no phasesince Oct 27, 2014 | Oct 27, 2014 | none ahead |
Also a collaborator on its studies: monitorcro.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Jul 28, 2006.
- Oct 27, 2014Vital 5's first study: no phase study in Low Back PainNew to Vital 5Vital 5 · NCT02293525
- May 24, 2016Phase 2 study in Pain, PostoperativePainReform · NCT02784327 · 15 enrolled · Israel
- Nov 4, 2016BioQ Pharma's first study: phase 3 study in Pain, PostoperativeNew to BioQ PharmaBioQ Pharma · NCT02959476 · 132 enrolled · United States
- Jun 25, 2018Taiwan Liposome's first study: phase 2 study in Hernia, InguinalNew to Taiwan LiposomeTaiwan Liposome · NCT03591146 · 65 enrolled · United States
- Feb 11, 2019Phase 2 study in Hallux ValgusTaiwan Liposome · NCT03838133 · 150 enrolled · United States
- Aug 14, 2021Cali Pharmaceuticals's first study: phase 2 study in Inguinal HerniorrhaphyNew to Cali PharmaceuticalsCali Pharmaceuticals · NCT05080959 · 105 enrolled · United States
- Dec 3, 2021Phase 3 study in Postsurgical Pain ManagementTaiwan Liposome · NCT05161637 · 415 planned
- Sep 13, 2022Egymedicalpedia's first study: phase 1 study in Hernia, InguinalNew to EgymedicalpediaEgymedicalpedia · NCT05549492 · 64 enrolled · Egypt
- Sep 27, 2022Jiangsu HengRui Medicine's first study: phase 2 study in Total Knee ArthroplastyNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT05561309 · 89 enrolled · China
- Nov 1, 2022Phase 3 study in BunionPainReform · NCT05773846 · 428 enrolled · United States
- Aug 25, 2024TLC Biopharmaceuticals's first study: phase 2 study in Postsurgical Pain ManagementNew to TLC BiopharmaceuticalsTLC Biopharmaceuticals · NCT06574269 · 120 planned · United States
- Jan 6, 2025PHARMAFINA's first study: phase 1 study in HealthyNew to PHARMAFINAPHARMAFINA · NCT06781632 · 12 enrolled · Turkey
- Jul 31, 2025Phase 2 study in Nerve BlockPHARMAFINA · NCT07131657 · 40 enrolled · Turkey (Türkiye)
- Oct 28, 2025Phase 3 study in Pain, PostoperativeTLC Biopharmaceuticals · NCT07222748 · 304 enrolled · United States
TargetBeta
“Sodium channel alpha subunit blocker”ChEMBL 37, by rule
Other programs on the same 10 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lidocainerule | Keenova Therapeutics | phase 4 | 63 |
| Lamotriginerule | GlaxoSmithKline | phase 4 | 61 |
| Carbamazepinerule | grin-therapeutics-inc | phase 4 | 21 |
| Dronedaronerule | Sanofi | phase 4 | 18 |
| chloroprocainerule | sintetica-sa | phase 4 | 8 |
| Riluzolerule | Sanofi | phase 4 | 6 |
| Prilocainerule | Haisco Pharmaceutical Group | phase 4 | 2 |
| Carticainerule | Laboratoires Thea | phase 4 | 1 |
| Phenytoinrule | Viatris | phase 3 | 10 |
| rufinamiderule | Eisai | phase 3 | 7 |
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07222748Pain, Postoperative · United States | 3 | Active, not recruiting | TLC Biopharmaceuticals | Jun 12, 2026 | 304 |
| NCT07131657Nerve Block · Turkey (Türkiye) | 2 | Completed | PHARMAFINA | Dec 3, 2025 | 40 |
| NCT06781632Healthy · Turkey | 1 | Completed | PHARMAFINA | Feb 20, 2025 | 12 |
| NCT06574269Postsurgical Pain Management · United States | 2 | Recruiting | TLC Biopharmaceuticals | Jul 2026 | 120 |
| NCT05773846Bunion · United States | 3 | Completed | PainReform | Jul 30, 2024 | 428 |
| NCT05561309Total Knee Arthroplasty · China | 2 | Active, not recruiting | Jiangsu HengRui Medicine | Dec 2024 | 89 |
| NCT05549492Hernia, Inguinal · Egypt | 1 | Completed | Egymedicalpedia | May 1, 2022 | 64 |
| NCT05161637Postsurgical Pain Management | 3 | Not yet recruiting | Taiwan Liposome | Dec 2025 | 415 |
| NCT05080959Inguinal Herniorrhaphy · United States | 2 | Completed | Cali Pharmaceuticals | Dec 31, 2021 | 105 |
| NCT03838133Hallux Valgus · United States | 2 | Completed | Taiwan Liposome | Mar 31, 2020 | 150 |
| NCT03591146Hernia, Inguinal · United States | 2 | Completed | Taiwan Liposome | Jan 5, 2019 | 65 |
| NCT02959476Pain, Postoperative · United States | 3 | Completed | BioQ Pharma | Aug 10, 2018 | 132 |
| NCT02784327Pain, Postoperative · Israel | 2 | UNKNOWN | PainReform | Apr 2017 | 15 |
| NCT02293525Low Back Pain | – | Withdrawn | Vital 5 | Jan 2016 | 0 |
| NCT01681966Pain, Postoperative · Israel | 2 | Completed | PainReform | May 4, 2016 | 15 |
| NCT00883194Pain · Israel | 2 | Completed | PainReform | Apr 2011 | 15 |
| NCT00358280Anesthesia,Spinal · China | 3 | Completed | AstraZeneca | 220 |
How it is read
Names in the registry
- “TLC590”, 10 entries
- “Ropivacaine”, 4 entries
- “Ropivacaine + Clonidine + Betamethasone”, 3 entries
- “ropivacaine”, 1 entry
- “HR18034;Ropivacaine Hydrochloride Injection”, 1 entry
Codes read as this program: PRF110.
Conditions, from the studies’ own filings
- Pain, Postoperative, 6 studies
- Hernia, Inguinal, 2 studies
- Bunion, 1 study
- Pain, 1 study
- Hallux Valgus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.